BioTelemetry (NASDAQ:BEAT) released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.08, Briefing.com reports. The company had revenue of $111.80 million during the quarter, compared to analyst estimates of $111.11 million. BioTelemetry had a net margin of 11.06% and a return on equity of 22.98%. BioTelemetry’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $0.46 earnings per share.
BEAT stock opened at $39.34 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.09 and a current ratio of 2.19. BioTelemetry has a one year low of $38.78 and a one year high of $80.92. The company has a market capitalization of $1.43 billion, a PE ratio of 20.73, a price-to-earnings-growth ratio of 2.14 and a beta of 1.32. The company’s 50 day moving average price is $45.61 and its two-hundred day moving average price is $56.15.
A number of equities research analysts recently weighed in on the stock. Sidoti lowered their target price on shares of BioTelemetry from $95.00 to $87.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. ValuEngine downgraded shares of BioTelemetry from a “hold” rating to a “sell” rating in a research note on Thursday, July 18th. Lake Street Capital set a $90.00 target price on shares of BioTelemetry and gave the company a “buy” rating in a research note on Wednesday, July 31st. Dougherty & Co reissued a “buy” rating and set a $75.00 price target (down from $81.00) on shares of BioTelemetry in a research note on Friday, April 26th. Finally, Raymond James downgraded shares of BioTelemetry from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $72.57.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Recommended Story: Quick Ratio
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.